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A b s t r a c t
Background: Remodelling process is associated with activity of such substances as transforming growth factor b1 (TGFb1),
basic fibroblast growth factor (bFGF, FGF2), or insulin like growth factor-1 (IGF-1). In the course of hypertension the remo-
delling of blood vessels and heart muscle takes place. Studies performed on animal models as well as clinical trials on
aetiology of left ventricular hypertrophy (LVH), documented elevated level of both mRNA and proteins of TGFb1 and IGF-1.
Aim: To analyse the correlation between cytokine levels and vascular and LV remodelling.
Methods: One hundred seven patients with essential hypertension (age 50 ± 10 years) as well as 50 healthy volunteers
participated in the study. Blood pressure was measured in the doctor’s office as well as using the ABPM method. The LVH
was diagnosed by echocardiographic examination, while ultrasound diagnostic was used to analyse the blood vessels remo-
delling measured as carotid intima–media thickness. Based on echocardiography results hypertensive patients were divided
into two groups — with or without LVH. Peripheral blood concentration of analysed cytokines was measured using Enzyme-
-Linked Immunosorbent Assay (ELISA). The results were compared with data obtained from control group of normotensive
participants.
Results: Values of single measurements of growth factors levels did not show significant differences between analysed groups
(p = 0.322), and they did not correlate with the blood pressure levels. The tendency to negative correlation between
parameters of diastolic LV function and plasma concentrations of IGF-1 and TGF was found. The value of IMT also did not
show significant correlation with TGFb1, bFGF and IGF-1 in all investigated groups.
Conclusions: The obtained results point to the limited usefulness of single measurements of TGFb1, bFGF as well as IGF-1
blood concentrations, as the potential prognostic factors of the remodelling of blood vessels and cardiac muscle in patients
with essential hypertension.
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INTRODUCTION
Transforming growth factor b1 (TGFb1), basic fibroblast growth
factor (bFGF, FGF2) and insulin like growth factor-1 (IGF-1)
are regulators of growth, cell proliferation and development
[1–3]. Previous studies have confirmed the role of cytokines
and growth factors in the processes of the blood vessel and
cardiac remodelling [4–6]. The observations on animal mo-
dels as well as in hypertensive patients with left ventricular
hypertrophy (LVH) documented the presence of increased
mRNA as well as protein levels of TGFb1 and IGF-1 [7, 8].
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Although the role of TGFb signalling pathway and bFGF in
the development of heart hypertrophy was highlighted by
transgenic animal studies [9, 10], the clinical studies investi-
gating the relationship between cardiac hypertrophy and blo-
od levels of cytokines and growth factors produced inconsi-
stent results [11, 12]. Increased mRNA levels of TGFb1 and
IGF-1 in cardiomyocytes of patients with idiopathic hyper-
trophic cardiomyopathy suggested the importance of these
substances in the regulation of cardiac hypertrophy [13, 14],
however involvement of TGFb1, bFGF and IGF-1 in the re-
gulation of LVH development remain an issue of major con-
troversy [11]. The observations on the role of cytokins as well
as growth factors in pathogenesis of blood vessels remodelling
also did not give one, simple answer. There is a theory about
protective role of cytokines stabilising atherosclerotic plug or
the reparative function of TGFb1, on the other hand there are
reports showing the pro-inflammatory activity of these factors,
promoting restenosis after angioplastic treatment [15].
Enzyme-Linked Immunosorbent Assay (ELISA) is the re-
commended, suitable assay for the measurement of cytoki-
nes and growth factors in peripheral blood [16]. This method
is both highly sensitive and specific [17].
The aim of this study was to compare the levels of TGFb1,
bFGF and IGF-1 in peripheral blood with the parameters of LV
structure as well as intima–media thickness (IMT) of the carotid
artery in hypertensive patients and control volunteers.
METHODS
Patients
One hundred fifty seven subjects (52% female, 48% male)
were recruited to participate in the study. The patient group
included 107 subjects with moderate hypertension (the dura-
tion of hypertension was up to 10 years), treated with the com-
bined antihypertensive therapy. The control group (n = 50)
consisted of age- and sex-matched healthy volunteers. The
exclusion criteria were as follows: secondary hypertension,
obesity (BMI > 30 kg/m2), diabetes, endocrinological disor-
ders, heart failure, arrhythmias, coronary heart disease, cardio-
myopathy, kidney disease, chronic lung disease, auto-immu-
nological disease, cancer and pregnancy.
The study was approved by the Jagiellonian University
Ethics Committee.
Procedures
The blood pressure was measured in the doctor’s office ac-
cording to the ESC/ESH guidelines [18]. A 24-hour ambula-
tory blood pressure monitoring (ABPM; SpaceLabs 90207,
Redmond, WA, USA) was also performed. An echocardio-
graphic M-mode and 2D examination (Hewlett-Packard,
SONOS 5500) was used to analyse the morphology and func-
tion of the LV. The LVH was defined as LV mass index (LVMI)
> 125 g/m2 in men and > 110 g/m2 in women [19]. The IMT
was measured in the common carotid artery, in the bulb of
the carotid artery and in the internal carotid artery, and was
used as the parameter of vessel wall remodelling (Hewlett-
-Packard, Sonos-5500, probe 13.5 MHz) [19]. The IMT was
expressed as the mean of three measurements taken in each
region of interest.
Biochemical analysis
The TGFb1, bFGF and IGF-1 levels were measured in venous
blood obtained after overnight fasting. Results were expres-
sed as the mean of results from triplicates of each sample. For
the TGFb1 analysis 5 mL of blood was taken (without using
a tourniquet) on EDTA. The blood sample was immediately
placed on ice. The plasma was spun for 30 min in 1000 xg
and later 10 min at 10 000 xg to remove platelets (which
contain a large amount of TGF) to obtain the platelet poor
plasma (PPP). The activation of TGFb1 in PPP was obtained
by acidification of PPP with 2.5 N acetic acid/10 urea and
later pH was adjusted up to 7.2–7.6 using 2.7 N NaOH/1M
HEPES. The analysis was done by ELISA following the Hu-
man TGF-b1 Immunoassay protocol (Quantikine, R&D Sys-
tems), method sensitivity was 7.0 pg/mL.
Blood samples for the bFGF measurements were taken
into tubes containing sodium citrate according to the proto-
col of Human FGF basic Immunoassay (Quantikine HS, R&D
Systems). Sensitivity of this method was 0.2 pg/mL. For the
IGF-1 measurement blood was collected into a tube without
anticoagulant. The IGF-1 in serum was measured by ELISA
according to a standard protocol (Human IGF-I Immunoas-
say, Quantikine, R&D Systems). The sensitivity of this me-
thod was 0.026 ng/mL. The inter- and intra-assay errors were
less than 5%.
Statistical methods
Statistical analysis was performed with the Statistica 6.0 PL for
Windows from Statsoft. Results are presented as mean ± SD
or numbers and percentages. The c2 test was used for com-
parison of proportions and unpaired t-test for comparison of
quantitative variables. The differences between variables in
the investigated groups were compared by analysis of varia-
nce (ANOVA), and the correlations between variables was
checked by regression analysis. Levels of statistical significance
were set at p < 0.05.
RESULTS
The hypertensive patients were divided according to the pre-
sence of LVH into the LVH (+) (n = 52) and LVH (–) (n = 55)
group. Ultrasound analysis of carotid arteries showed signifi-
cantly increased IMT in hypertensive patients with LVH com-
pared to other groups [p = 0.002 for control, p = 0.034 for
LVH (–)] (Fig. 1).
Single measurements of TGFb1, IGF-1 and bFGF levels
did not show any differences between the groups (p = 0.322)
(Fig. 2). The mean IGF blood concentration measured was:
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in control group 72.3 ng/mL; in group LVH (+) 78.5 ng/mL
and in LVH (–) 78 ng/mL. The TGFb1 level was respectively:
2.85 pg/ml in controls, 2.74 pg/mL in the LVH (+) group and
2.38 pg/ml in the LVH (–) group. The bFGF mean concentra-
tion was 2.63 pg/mL in control group; 1.91 pg/mL in LVH
(+) and 2.21 pg/mL in LVH (–).
Additional analysis of the investigated factors (TGFb1,
bFGF and IGF-1) in controls and hypertensive patients, in-
dependently to the presence/absence of LVH, did not show
any significant correlations. The ultrasound measurements
of carotid IMT did not show significant correlation with
TGFb1, bFGF and IGF-1 blood levels (Fig. 3). Regression
analysis did not revealed significant correlation between
TGFb1, bFGF, and IGF-1 levels in peripheral blood and
blood pressure, either measured in the office or monitored
with ABPM (Table 1).
The analysis of LV function showed a tendency toward
a negative correlation between the parameters of diastolic
dysfunction (E/A ratio and IVRT) and blood levels of IGF-1
and between the E wave deceleration time and blood levels
of TGFb1 (Table 2).
DISCUSSION
Among numerous factors that influence vascular wall remo-
delling and the process of LVH in the course of hypertension,
the activity of different cytokines and growth factors have been
demonstrated [5, 7, 20]. Our results confirmed the lack of
correlation between the plasma levels of TGFb1, bFGF and
IGF-1 and the LV remodelling in the course of hypertension.
These results are in concordance with other reports descri-
bing the lack of association between the cytokine serum le-
vel and LV mass in hypertensive patients [21].
Figure 1. Comparision of the intima-media thickness in the
studied groups; IMT — intima-media thickness; BCA — bulb of
carotid artery; CCA — common carotid artery; ICA — internal
carotid artery; LVH (+) and LVH (–) — group of hypertensive
patients with LVH and without LVH; *p < 0.05 vs LVH (–),
#p < 0.05 vs Controls
Figure 2. Comparison of the levels of TGFb1, bFGF and IGF-1 in
the studied groups. Abbreviations as in Figure 1
Figure 3. Relationship between TGFb1, bFGF and IGF-1 levels
and intima–media thickness (IMT) parameters in three investiga-
ted groups. Abbreviations as in Figure 1
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groups. The antihypertensive medication was an important dif-
ference between the controls and the hypertensive patients, but
the treatment could not be discontinued for ethical reasons.
The cardiovascular remodelling in hypertension has been
analysed for several years [5, 21, 22]. In our study considerable
attention was paid to the recruitment and homogeneity of the
Table 1. The correlation between systolic (SBP) and diastolic (DBP) blood pressure values and the TGFb1, bFGF and IGF-1 levels in
peripheral blood of hypertensive patients (with and without LVH) and controls.
Office blood pressure level
Blood pressure Factor Coefficient of line inclination P
SBP [mm Hg] TGF [pg/mL] 0.057 0.943
bFGF [pg/mL] –0.532 0.254
IGF-1 [ng/mL] –0.029 0.326
DBP [mm Hg] TGF [pg/mL] –0.135 0.789
bFGF [pg/mL] –0.733 0.091
IGF-1 [ng/mL] –0.045 0.153
Ambulatory blood pressure monitoring
Parameter Factor Coefficient of P Parameter Factor Coefficient of P
line inclination line inclination
SBP 24 h [mm Hg] TGF [pg/mL] –0.148 0.067 DBP 24 h [mm Hg] TGF [pg/mL] –0.241 0.053
bFGF [pg/mL] 0.045 0.591 bFGF [pg/mL] –0.019 0.818
IGF-1 [ng/mL] 0.006 0.943 IGF-1 [ng/mL] –0.049 0.961
SBP day [mm Hg] TGF [pg/mL] –0.138 0.206 DBP day [mm Hg] TGF [pg/mL] –0.112 0.165
bFGF [pg/mL] 0.002 0.982 bFGF [pg/mL] –0.039 0.843
IGF-1 [ng/mL] –0.017 0.843 IGF-1 [ng/mL] –0.064 0.791
SBP night [mm Hg] TGF [pg/mL] –0.108 0.102 DBP night [mm Hg] TGF [pg/mL] –0.119 0.087
bFGF [pg/mL] –0.001 0.995 bFGF [pg/mL] –0.004 0.101
IGF-1 [ng/mL] –0.043 0.862 IGF-1 [ng/mL] –0.040 0.630
SBP 24 h — mean level of SBP during 24 h; DBP 24 h — mean level of DBP during 24 h; SBP day — mean level of SBP measured during the day (6am–
–10pm); DBP day — mean level of DBP measured during the day (6am–10pm); SBP night — mean level of SBP measured during the night (10pm–6am);
DBP night — mean level of DBP measured during the night (10pm–6am)
Table 2. Influence of TGFb1, bFGF and IGF-1 level on the left ventricle parameters in all investigated groups: LVH (+), LVH (–) and control
Parameter Factor Coefficient of P Parameter Factor Coefficient of P
line inclination line inclination
LVMI [g/m2] TGF [pg/mL] –0.013 0.876 IVRT [ms] TGF [pg/mL] –0.085 0.758
bFGF [pg/mL] –0.127 0.189 bFGF [pg/mL] 0.002 0.581
IGF-1 [ng/mL] –0.015 0.983 IGF-1 [ng/mL] 0.035 0.147
IVSD [mm] TGF [pg/mL] –0.018 0.823 E [cm/s] TGF [pg/mL] –0.128 0.112
bFGF [pg/mL] –0.103 0.202 bFGF [pg/mL] 0.005 0.832
IGF-1 [ng/mL] 0.003 0.973 IGF-1 [ng/mL] –0.063 0.661
PWD [mm] TGF [pg/mL] –0.067 0.415 A [cm/s] TGF [pg/mL] 0.072 0.505
bFGF [pg/mL] –0.126 0.130 bFGF [pg/mL] –0.039 0.753
IGF-1 [ng/mL] –0.003 0.973 IGF-1 [ng/mL] –0.168 0.128
E/A TGF [pg/mL] –0.114 0.725 decE [ms] TGF [pg/mL] 0.146 0.064
bFGF [pg/mL] 0.001 0.993 bFGF [pg/mL] 0.028 0.919
IGF-1 [ng/mL] –0.120 0.117 IGF-1 [ng/mL] 0.057 0.416
LVMI — left ventricular mass index; IVSD — inter-ventricular septum in diastole; IVRT — intra-ventricular relaxation time; PWD — posterior wall in
diastole; E, A — wave E and wave A parameters of left ventricle relaxation; decE — deceleration of wave E
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–S25.
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abnormalities and obesity-associated hypertension: relation-
ship with overproduction of circulating transforming growth
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13. Li G, Borger MA, Williams WG, Weisel RD et al. Regional over-
expression of insulin-like growth factor-I and transforming
growth factor-beta1 in the myocardium of patients with hyper-
trophic obstructive cardiomyopathy. J Thorac Cardiovasc Surg,
2002; 123: 89–95.
14. Li RK, Li G, Mickle DA, Weisel RD et al. Overexpression of
transforming growth factor-beta1 and insulin-like growth fac-
tor-I in patients with idiopathic hypertrophic cardiomyopathy.
Circulation, 1997; 96: 874–881.
15. Dabek J, Kułach A, Monastyrska-Cup B et al. Transforming
growth factor beta and cardiovascular diseases: the other facet
of the ’protective cytokine’. Pharmacol Rep, 2006; 58: 799–805.
16. Ito Y, Nakachi K, Imai K, Hashimoto S et al. Stability of fro-
zen serum levels of insulin-like growth factor-I, insulin-like
growth factor-II, insulin-like growth factor binding protein-3,
transforming growth factor beta, soluble Fas, and superoxide
dismutase activity for the JACC study. J Epidemiol, 2005; 15:
S67–S73.
17. Pulford BE, Ishii DN. Uptake of circulating insulin-like growth
factors (IGFs) into cerebrospinal fluid appears to be indepen-
dent of the IGF receptors as well as IGF-binding proteins. En-
docrinology, 2001; 142: 213–220.
18. Summary of the 2007 European Society of Hypertension (ESH)
and European Society of Cardiology (ESC) guidelines for the
management of arterial hypertension. Vasc Health Risk Manag,
2007; 3: 783–795.
Our study did not show any significant relationship be-
tween investigated factors and blood vessels structure. The
presented results are in agreement with previous clinical ob-
servations which did not find any correlation between IMT
value and IGF-1 level [23, 24].
The role of TGFb1, as well as IGF-1 in the development
of heart muscle hypertrophy has been confirmed by several
in vitro studies [25, 26]. In an in vivo model increased mRNA
and protein levels of TGFb1 and of bFGF in cardiomyocytes
of hypertrophied heart have been demonstrated [2, 27]. Only
of non-significant tendency towards a correlation between
the LV diastolic dysfunction and the studied cytokines was
observed. These findings argue for the local, intramuscular
role of generated TGFb1, and IGF-1 in the pathogenesis of
cardiovascular wall remodelling [19, 28]. The impaired re-
laxation of the LV precedes the development of LVH in hy-
pertensive patients [29]. There exists a single report about
the possible beneficial effect of IGF-1 for diastolic relaxa-
tion [30]. The correlation between overproduction of TGFb1
and impaired filling of the LV in obese and overweight hy-
pertensive patients was reported [11]. However, such a cor-
relation did not reach significance in hypertensive patients
with normal body mass index [11], which is in line with the
results obtained in our study.
Our results do not exclude the local role of TGFb1, bFGF
and IGF-1 in the pathogenesis of the hypertension-associa-
ted vessel wall remodelling or LVH. It has been demonstra-
ted that growth factors act mainly in the area of their produc-
tion [19]. The blood levels obtained by single measurements
may not reflect the local concentration of cytokine in the tar-
get organ. Both experimental and clinical studies failed to
document the correlation between TGFb1, bFGF and IGF-1
blood levels and tissue remodelling in the course of hyper-
tension [31]. However, it may be speculated that monitoring
the level of these factors in the early stages of hypertension
performed individually may be useful for the early detection
of decreased relaxation of LV musculature, which precedes
the development of LVH [29].
CONCLUSIONS
Our observations bring into question the importance of the
single measurements of TGFb1, bFGF and IGF-1 levels in pe-
ripheral blood as the predictive factors of cardiovascular re-
modelling in the course of hypertension.
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S t r e s z c z e n i e
Wstęp: Przebudowa tkanek wiąże się z produkcją takich czynników, jak TGFb1 (transforming growth factor b1), bFGF (basic
fibroblast growth factor, FGF2) czy IGF-1 (insulin-like growth factor-1). W przebiegu nadciśnienia tętniczego dochodzi do
przebudowy naczyń i serca. Badania przeprowadzone na modelach zwierzęcych oraz próby kliniczne nad przerostem ścia-
ny lewej komory (LVH) w przebiegu nadciśnienia tętniczego potwierdziły podwyższone stężenie mRNA oraz białka TGFb1
i IGF-1.
Cel: Celem niniejszej pracy była ocena związku stężeń TGFb1, bFGF oraz IGF-1, mierzonych we krwi obwodowej, z para-
metrami struktury lewej komory oraz z wartościami grubości kompleksu intima–media (IMT), wskaźnika przebudowy ścian
naczyń u pacjentów z nadciśnieniem tętniczym, u których rozwinęły się (lub nie) zmiany narządowe, oraz u osób zdrowych
z prawidłowym ciśnieniem tętniczym.
Metody: W badaniu uczestniczyło 107 pacjentów z nadciśnieniem tętniczym (w wieku 50 ± 10 lat) oraz 50 zdrowych
ochotników dobranych pod względem płci i wieku. Pomiary ciśnienia tętniczego przeprowadzono w gabinecie lekarskim
oraz wykonano 24-godzinny nieinwazyjny pomiar ciśnienia tętniczego (ABPM). Przerost lewej komory rozpoznawano na
podstawie badania echokardiograficznego, a diagnostyka ultrasonograficzna obrazowała przebudowę naczyń na podstawie
wartości IMT. Uwzględniając wyniki badania echokardiograficznego pacjentów z nadciśnieniem podzielono na dwie grupy
— z LVH i bez LVH. Stężenie we krwi obwodowej badanych cytokin mierzono przy użyciu metody ELISA (Enzyme-Linked
Immunosorbent Asay).
Wyniki: Stężenia czynników wzrostu w pojedynczym pomiarze nie różniły się istotnie między badanymi grupami (p = 0,322);
nie korelowały także z wartościami ciśnienia tętniczego. Zaobserwowano tendencję do negatywnej korelacji pomiędzy pa-
rametrami funkcji rozkurczowej lewej komory a stężeniami IGF-1 i TGF w surowicy krwi. Wartość IMT w badanych grupach
również nie wykazała istotnego związku ze stężeniem TGFb1, bFGF oraz IGF-1.
Wnioski: Uzyskane wyniki wskazują na ograniczoną przydatność diagnostyczną pojedynczego pomiaru stężeń TGFb1, bFGF
oraz IGF-1 w surowicy krwi obwodowej jako czynnika prognostycznego przebudowy serca oraz ścian naczyń u pacjentów
z nadciśnieniem, a przez to w stratyfikacji ryzyka osób z nadciśnieniem tętniczym.
Słowa kluczowe: bFGF, czynniki wzrostu, IGF-1, IMT, przerost lewej komory, nadciśnienie tętnicze, TGFb1
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